Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
Sponsor: YM BioSciences
Terminated
Cohort 2 not going forward. Manadate changes in Company
Other terminated trials from YM BioSciences
Other Colorectal Cancer trials with similar outcome
This PHASE2 trial investigates Colorectal Cancer and is currently terminated or withdrawn. YM BioSciences leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- YM BioSciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barrie, Canada , Calgary, Canada , Kitchener, Canada , London, Canada , Mississauga, Canada , Newmarket, Canada , Ottawa, Canada , Sault Ste. Marie, Canada , St. John's, Canada , Toronto, Canada and 1 more location